You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 25, 2025

CLINICAL TRIALS PROFILE FOR INSULIN SUSP ISOPHANE RECOMBINANT HUMAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Insulin Susp Isophane Recombinant Human

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00658099 ↗ Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® Completed Novo Nordisk A/S 2007-11-01 This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.
NCT00665808 ↗ Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany Completed Novo Nordisk A/S 2007-10-01 This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings.
NCT01122979 ↗ Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. Completed Sanofi Phase 4 2010-07-01 Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group. Secondary Objectives: - Glycemic control, measured by HbA1c and FPG (fasting plasma glucose) at baseline and after each period of treatment. - Incidence of confirmed symptomatic and nocturnal hypoglycemia. - Incidence of confirmed severe hypoglycemia (< 36mg/dL or need of help to recover). >Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events.
NCT01680185 ↗ Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation Completed Medical University of Vienna Phase 3 2012-08-01 The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. Patients in the SAPT-NODAT study will be followed through 24 months post-transplantation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Susp Isophane Recombinant Human

Condition Name

Condition Name for Insulin Susp Isophane Recombinant Human
Intervention Trials
Diabetes Mellitus, Type 2 4
Diabetes Mellitus 3
Hyperglycemia 2
Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Susp Isophane Recombinant Human
Intervention Trials
Diabetes Mellitus 7
Diabetes Mellitus, Type 2 4
Hyperglycemia 2
Diabetes Mellitus, Type 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Susp Isophane Recombinant Human

Trials by Country

Trials by Country for Insulin Susp Isophane Recombinant Human
Location Trials
United States 16
Canada 4
Germany 4
Burkina Faso 2
Romania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Susp Isophane Recombinant Human
Location Trials
Idaho 1
Florida 1
California 1
Arizona 1
Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Susp Isophane Recombinant Human

Clinical Trial Phase

Clinical Trial Phase for Insulin Susp Isophane Recombinant Human
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Susp Isophane Recombinant Human
Clinical Trial Phase Trials
Completed 8
Terminated 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Susp Isophane Recombinant Human

Sponsor Name

Sponsor Name for Insulin Susp Isophane Recombinant Human
Sponsor Trials
Novo Nordisk A/S 2
Medical University of Vienna 2
Profil Institut für Stoffwechselforschung GmbH 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Susp Isophane Recombinant Human
Sponsor Trials
Other 11
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Oral and Recombinant Human Insulin: Clinical Trials, Market Analysis, and Projections

Introduction to Insulin Therapy

Insulin is a crucial hormone for regulating blood glucose levels, and its therapeutic use is vital for managing diabetes. Traditional insulin therapies involve injections, but recent advancements are paving the way for more convenient and effective delivery methods.

Current State of Insulin Therapy

Traditional Insulin Forms

Traditional insulin therapies include short-acting, intermediate-acting, and long-acting insulins. For example, Humulin R (insulin human recombinant) is a short-acting insulin that takes effect within 30 minutes and has a duration of activity of approximately 4 to 12 hours[4].

Recombinant Human Insulin

Recombinant human insulin, produced through recombinant DNA technology, has revolutionized insulin production. This method involves introducing a gene into bacteria like Escherichia coli to produce human insulin. Products like Insuman and Humulin R are examples of recombinant human insulins that have been widely used for both type 1 and type 2 diabetes[2][4].

Clinical Trials Update: Oral Insulin

Human Trials in 2025

A significant development in insulin therapy is the upcoming human clinical trials for oral insulin. Researchers from UiT The Arctic University of Norway and the University of Sydney have developed an oral insulin that has shown promising results in animal models. This oral insulin, attached to nanocarriers, is set to undergo human clinical trials in 2025. The trials will focus on the safety of the oral insulin and its ability to avoid hypoglycemia in both healthy and type 1 diabetic patients[1].

Trial Phases and Objectives

The clinical trials will be conducted in three phases. Phase I will investigate the safety of the oral insulin and the incidence of hypoglycemia. If successful, phase II trials will explore how this oral insulin can replace injections for diabetic patients. The researchers are optimistic about reproducing the positive results seen in baboons in human subjects, which would be a significant breakthrough[1].

Market Analysis of Recombinant Human Insulin

Global Market Size and Growth

The global recombinant human insulin market is experiencing robust growth. In 2022, the market size was valued at approximately USD 32.35 billion and is expected to reach USD 55.99 billion by 2032, growing at a compound annual growth rate (CAGR) of about 8.5% during the forecast period[3].

Key Drivers of Market Growth

Several factors are driving the growth of the recombinant human insulin market:

  • Increasing Diabetes Prevalence: The rising number of diabetic patients worldwide is a major driver. By 2030, the number of adults with diabetes is expected to reach 643 million[1][3].
  • Technological Advancements: Innovations in insulin delivery systems, formulations, and monitoring technologies enhance patient convenience and compliance[3].
  • Healthcare Infrastructure Expansion: Improvements in healthcare infrastructure and expanded healthcare coverage contribute to increased access to insulin therapies[3].
  • Growing Geriatric Population: The aging global population is more prone to diabetes, further fueling the demand for insulin therapies[3].

Market Projections

Regional Analysis

The global human insulin market is expected to grow significantly across various regions. North America is currently the largest market, but the Asia-Pacific region is expected to be the fastest-growing due to its large and increasing diabetic population[5].

Distribution Channels

The distribution of human insulin is primarily through hospitals, retail pharmacies, and online pharmacies. The expansion of healthcare facilities and favorable reimbursement policies are key factors in the market's growth[5].

Impact of Oral Insulin on the Market

Potential Market Disruption

If oral insulin proves successful in human trials, it could significantly disrupt the current insulin market. Oral insulin offers the potential for more precise delivery, reducing unwanted side effects associated with traditional injections. This could lead to increased patient compliance and a shift in market demand towards oral insulin products[1].

Competitive Landscape

The introduction of oral insulin will likely influence the competitive landscape of the insulin market. Companies like Novo Nordisk and others that dominate the current market may need to adapt to include oral insulin in their product portfolios to remain competitive[5].

Key Takeaways

  • Oral Insulin Trials: Human clinical trials for oral insulin are set to begin in 2025, offering a potential breakthrough in diabetes management.
  • Market Growth: The global recombinant human insulin market is expected to grow significantly, driven by increasing diabetes prevalence, technological advancements, and healthcare infrastructure expansion.
  • Regional Growth: North America is the largest market, but the Asia-Pacific region is expected to be the fastest-growing.
  • Distribution Channels: Hospitals, retail pharmacies, and online pharmacies are key distribution channels.
  • Potential Disruption: Successful oral insulin could disrupt the market, leading to increased patient compliance and a shift in market demand.

FAQs

What is the current status of oral insulin trials?

Oral insulin trials are set to begin in human clinical trials in 2025, following successful tests in animal models.

How does recombinant human insulin differ from traditional insulin?

Recombinant human insulin is produced using recombinant DNA technology, where bacteria are genetically modified to produce human insulin, unlike traditional insulin which was often derived from animals.

What are the key drivers of the global recombinant human insulin market?

Key drivers include increasing diabetes prevalence, technological advancements, healthcare infrastructure expansion, and a growing geriatric population.

Which region is expected to be the fastest-growing in the human insulin market?

The Asia-Pacific region is expected to be the fastest-growing due to its large and increasing diabetic population.

How could oral insulin impact the current insulin market?

Oral insulin could disrupt the market by offering a more precise and convenient delivery method, potentially increasing patient compliance and shifting market demand.

Sources

  1. New Atlas: Oral insulin set for human trials in 2025, may be available in 2-to-3 years.
  2. European Medicines Agency (EMA): Insuman.
  3. GlobeNewswire: Latest Global Recombinant Human Insulin Market Size/Share.
  4. RxList: Humulin R (Insulin (Human Recombinant)).
  5. GreyViews: Human Insulin Market- Size| Growth| Market Analysis Till 2030.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.